Brief: Alvotech Signs U.S. Agreement To Expand Access For Newly Approved High-Concentration Interchangeable Biosimilar To Humira® (adalimumab)

Alvotech SA

19/04/2024 13:49

April 19 (Reuters) - Alvotech SA  ALVO.O :
    * ALVOTECH SIGNS U.S. AGREEMENT TO EXPAND ACCESS FOR NEWLY
APPROVED HIGH-CONCENTRATION INTERCHANGEABLE BIOSIMILAR TO
HUMIRA® (ADALIMUMAB)
    * ALVOTECH SA - CURRENT MULTI-PRODUCT COMMERCIALIZATION
PARTNERSHIP BETWEEN TEVA PHARMACEUTICALS AND ALVOTECH REMAINS
UNCHANGED
    * ALVOTECH SA - AGREEMENT BROADENS PATIENT ACCESS AND
FURTHER
COMMITMENT TO AVAILABILITY OF VITAL BIOLOGICS IN U.S. AND
GLOBALLY
    * ALVOTECH SA - TEVA WILL CONTINUE TO COMMERCIALIZE
ADALIMUMAB-RYVK UNDER SIMLANDI BRAND IN U.S
    * ALVOTECH SA - LONG-TERM AGREEMENT WITH A STRATEGIC PARTNER
TO
FURTHER ENHANCE ACCESS TO ADALIMUMAB-RYVK IN U.S. MARKET

Source text for Eikon:  ID:nGNX9y2S0B 
Further company coverage:  ALVO.O